Atara Biotherapeutics Inc
Most Recent
Understanding Atara Biotherapeutics’ Licensing and Collaboration Agreements
In September 2014, Atara Biotherapeutics (ATRA) entered into an exclusive option agreement with Memorial Sloan Kettering Center (or MSK).
A Deeper Look at Atara Biotherapeutics’ ATA129, ATA520, and ATA230
In April 2017, Atara Biotherapeutics (ATRA) entered into an agreement with Merck (MRK) to evaluate ATA129 in combination with Merck’s Keytruda.
Where Atara Biotherapeutics Stands This January: Analyst Ratings
Atara Biotherapeutics (ATRA) is a company focused on developing novel T-cell immunotherapy treatments for patients with cancer and multiple sclerosis.
Inside Atara Biotherapeutics’ Promising Product Pipeline
Atara’s most advanced T-cell therapy in development is its ATA129, which is under development for the treatment of cancer patients with Epstein Barr virus.
XBI Recovers from Its Slump
The SPDR S&P Biotech ETF (XBI) and the iShares Nasdaq Biotechnology ETF (IBB) were the top biotechnology ETFs last week, returning 5.3%, and 3.7%.
Analyzing The Baupost Group’s Holdings in 4Q14
The Baupost Group generated $21.5 billion in returns over its history. The recent 13F filing revealed that its 4Q14 portfolio declined more to $5.09 billion.
Baupost discloses stake in Paratek Pharmaceuticals
Seth Klarman’s The Baupost Group added a 12.04% stake in Paratek Pharmaceuticals, Inc. (PRTK), according to a 13G filing in December.
Forward Pharma: One of Baupost’s new positions
Seth Klarman’s The Baupost Group added a 11.72% stake in Forward Pharma (FWP). A November 13G filing shows the fund owns 5,367,300 Forward Pharma shares.
Baupost nearly doubles position in Cheniere Energy
In its 13G filing in January, The Baupost Group upped its stake in Cheniere Energy (LNG), giving it 10.01% stake in LNG and nearly doubling its 3Q14 filing.
